Showing 7751-7760 of 10548 results for "".
- Novartis to Present CSU, HS Data for Remibrutinib, Secukinumabhttps://practicaldermatology.com/news/Novartis-Present-CSU-HS-Data-Remibrutinib-Secukinumab/2471383/Novartis announced it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting and the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organizatio
- Beyond the Surface: Updates in Itch Treatmenthttps://practicaldermatology.com/news/beyond-the-surface-updates-in-itch-treatment/2471285/
- LEVEL UP: Switching from Dupilumab to Upadacitinib Promising for AD Patientshttps://practicaldermatology.com/news/level-up-switching-from-dupilumab-to-upadacitinib-promising-for-ad-patients/2468483/New research presented at the 44th Annual Fall Clinical Dermatology Conference offered compelling results from th
- Study: Adherence Declines With Complex Atopic Dermatitis Regimenshttps://practicaldermatology.com/news/dherence-declines-complex-atopic-dermatitis-regimens-aad-guidelines/2468194/New American Academy of Dermatology (AAD) guidelines emphasize complex topical regimens for atopic dermatitis (AD), but adherence issues may limit their effectiveness, according to new research. According to a recent article in the Journal of Drugs in Dermatology, the AAD released
- Study: LTX-315 Shows 86% Reduction in BCC Tumor Sizehttps://practicaldermatology.com/news/study-ltx-315-shows-86-reduction-bcc-tumor-size/2467796/Lytix Biopharma has announced promising preliminary results from a phase 2 clinical trial evaluating the efficacy of LTX-315, its candidate drug for the treatment of basal cell carcinoma (BCC). The trial was conducted by Verrica Pharmaceuticals, according to a news release, and the result
- Analysis: Age, Number of Mohs Surgery Stages Linked with Higher-risk Basal Cell Carcinomahttps://practicaldermatology.com/news/analysis-age-number-mohs-surgery-stages-linked-higher-risk-basal-cell-carcinoma/2467270/
- Study Reveals Skin Cancer Surveillance Gaps in Transplant Recipientshttps://practicaldermatology.com/news/study-reveals-skin-cancer-surveillance-gaps-transplant-recipients/2467203/
- Report: Aesthetic Lasers Market to Surge 16.6% Annually Through 2032https://practicaldermatology.com/news/report-aesthetic-lasers-market-surge-166-annually-through-2032/2467086/Markets for aesthetic lasers are projected to $5.392 billion by 2032, according to a new report fro
- Study Links Oral Contraceptives and CYP1B1 Variant to Alopecia Riskhttps://practicaldermatology.com/news/study-links-oral-contraceptives-and-cyp1b1-variant-alopecia-risk/2463230/Recent research published in JAMA Dermatology highlighted a potential linkage between the use of oral contraceptive pills (OCP) and the protective effect of a common missense variant in the CYP1B1 gene on the risk of developing frontal fibrosing alopecia (FFA). Researchers for the case-co
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w